Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment
Monday, 31 March 2025 () LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced that the Japanese Patent Office has granted Poxel a new patent (nĀ°7635474) covering the use of Imeglimin in type-2 diabetic patients with moderate to severe r
Monday, 31 March 2025 ()
